Glycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDGNovember 18, 2024Read article
Aura Biosciences Reports Second Quarter 2024 Financial Results and Business HighlightsNovember 18, 2024Read article
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual MeetingNovember 18, 2024Read article
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024November 18, 2024Read article
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 TrialNovember 18, 2024Read article
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 18, 2024Read article
CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive OfficerNovember 18, 2024Read article
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 18, 2024Read article
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 18, 2024Read article
